Roche Launches Quantitative Test for Coronavirus Antibodies
September 18 2020 - 2:09AM
Dow Jones News
By Kim Richters
Swiss health-care giant Roche Holding AG said Friday that it is
launching a new test to quantitatively measure the level of
coronavirus antibodies.
Roche said the Elecsys Anti-SARS-CoV-2 S antibody test would
specifically target antibodies against the SARS-CoV-2 spike
protein, which is responsible for binding to the host cell
receptor.
"As the possibility of an effective SARS-CoV-2 vaccine becomes a
reality, quantitative measurement of antibodies will be crucial in
the evaluation of any potential vaccine," Thomas Schinecker, chief
executive at Roche's diagnostics division, said.
"The new quantitative Elecsys antibody test can play a pivotal
role in vaccine clinical trials as well as helping clinicians
assess patients immune response," he said.
It is the 12th test in Roche's coronavirus portfolio and the
company has filed for emergency use authorization from the U.S.
Food and Drug Administration.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
September 18, 2020 01:54 ET (05:54 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024